Condition: Colorectal Cancer Stage II · Colorectal Cancer Stage III · Sponsor: BioNTech SE
This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer, or Stage II (high risk)/Stage III colon cancer.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Marin Cancer Care | Greenbrae, California, United States | — |
| Rocky Mountain Cancer Centers - Denver Midtwon | Denver, Colorado, United States | — |
| Indiana University Melvin and Bren Simon Comprehensive Cancer | Indianapolis, Indiana, United States | — |
| Allina Health | Minneapolis, Minnesota, United States | — |
| Oncology Hematology Care Clinical Trials | Cincinnati, Ohio, United States | — |
| Rhode Island Hospital | Providence, Rhode Island, United States | — |
| Sarah Cannon (Tennessee Oncology - Nashville) | Nashville, Tennessee, United States | — |
| Texas Oncology, P.A. - Austin | Austin, Texas, United States | — |
| Texas Oncology-Baylor Charles A. Sammons Cancer Center | Dallas, Texas, United States | — |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | — |
| Texas Oncology-San Antonio Medical Center | San Antonio, Texas, United States | — |
| Texas Oncology - Northeast Texas | Tyler, Texas, United States | — |
+ 74 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.